Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non-Current Debt (2016 - 2026)

Ironwood Pharmaceuticals' Non-Current Debt history spans 10 years, with the latest figure at $385.0 million for Q4 2025.

  • On a quarterly basis, Non-Current Debt changed 0.0% to $385.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $385.0 million, a 0.0% change, with the full-year FY2025 number at $385.0 million, changed 0.0% from a year prior.
  • Non-Current Debt hit $385.0 million in Q4 2025 for Ironwood Pharmaceuticals, roughly flat from $385.0 million in the prior quarter.
  • Over the last five years, Non-Current Debt for IRWD hit a ceiling of $425.0 million in Q2 2024 and a floor of $275.0 million in Q1 2024.
  • Historically, Non-Current Debt has averaged $368.2 million across 3 years, with a median of $385.0 million in 2024.
  • The widest YoY moves for Non-Current Debt: up 40.0% in 2025, down 9.41% in 2025.
  • Tracing IRWD's Non-Current Debt over 3 years: stood at $300.0 million in 2023, then grew by 28.33% to $385.0 million in 2024, then changed by 0.0% to $385.0 million in 2025.
  • Business Quant data shows Non-Current Debt for IRWD at $385.0 million in Q4 2025, $385.0 million in Q3 2025, and $385.0 million in Q2 2025.